Awad, Robin Maximilian
De Vlaeminck, Yannick
Meeus, Fien
Ertveldt, Thomas
Zeven, Katty
Ceuppens, Hannelore
Goyvaerts, Cleo
Verdonck, Magali
Salguero, Gustavo
Raes, Geert
Devoogdt, Nick
Breckpot, Karine
Funding for this research was provided by:
Fonds Wetenschappelijk Onderzoek (1S05022N)
Article History
Received: 2 April 2023
Accepted: 26 October 2023
First Online: 3 November 2023
Competing interests
: GR, ND and KB have patents on the use of K2 for imaging and therapy purposes (WO2019166622A1; Human pd-l1-binding immunoglobulins). GR and ND hold ownership interest in Abscint NV/SA and in Precirix. The remaining authors declare no competing interests.